SCHEMBL19345071

SCHEMBL19345071

Nc1nccc(Br)c1N=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGMT P16455 3/20 0.35
▸ NOS3 P29474 6/20 0.34
▸ NOS2 P35228 6/20 0.34
▸ CSNK2A1 P68400 2/20 0.33
▸ CDK1 P06493 2/20 0.33
▸ CDK2 P24941 2/20 0.33
▸ HIPK2 Q9H2X6 1/20 0.33
▸ CCNB1 P14635 1/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ CCNA1 P78396 1/20 0.33
▸ NOS1 P29475 3/20 0.32
▸ DAO P14920 1/20 0.32
▸ F12 P00748 1/20 0.32
▸ PLAU P00749 1/20 0.32
▸ NCF1 P14598 1/20 0.32
▸ BACE1 P56817 1/20 0.32
▸ MAPT P10636 2/20 0.32
▸ KMT2A Q03164 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10765947 0.78 NOS3 (0.37) MGMTNOS3NOS2CDK1CDK2
SCHEMBL12528205 0.75 NOS2 (0.54) MGMTNOS3NOS2CDK1CDK2
SCHEMBL12503575 0.75 MGMT (0.35) MGMTNOS3NOS2CDK1CDK2
SCHEMBL19363563 0.71 NCF1 (0.32) MGMTNCF1MAPT
SCHEMBL6711366 0.70 — —
SCHEMBL11808156 0.70 — —
SCHEMBL29562566 0.70 — —
SCHEMBL12528297 0.68 HTT (0.36) NOS3NOS2CDK2CCNA2CCNA1
SCHEMBL2491871 0.67 CDK2 (0.37) MGMTCDK1CDK2CCNB1CCNA2
SCHEMBL1516762 0.67 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2019-02-21 — — US disclosed
US-10023572-B2 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-07-17 — — US disclosed
US-20180148444-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-05-31 — — US disclosed
US-20180141963-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2018-05-24 — — US disclosed
US-20170260209-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148444-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MGMT 4038/4885NOS3 929/4885NOS2 1767/4885
US-20180141963-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MGMT 2972/4885NOS3 1052/4885NOS2 2616/4885
US-20170260209-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT3, WNT1, WNT3A MGMT 2925/4885NOS3 968/4885NOS2 2652/4885
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MGMT 4038/4885NOS3 929/4885NOS2 1767/4885
US-10023572-B2 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A MGMT 4038/4885NOS3 929/4885NOS2 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback